[8-K] CERO THERAPEUTICS HOLDINGS, INC. Reports Material Event

Rhea-AI Filing Summary

CERO Therapeutics Holdings reported that a Nasdaq Hearings Panel denied its request for continued listing, citing noncompliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement of $2,500,000 under Rule 5550(b). As a result, CERO’s common stock will be suspended from trading on October 31, 2025.

The company has requested review by the Nasdaq Listing and Hearing Review Council and has begun the process to trade on the OTC Markets, while also considering other exchange options. CERO plans to continue its clinical trials, noting early observations for CER-1236 in initial AML patients at low dose with rapid cell expansion and no observed toxicity, and intends to proceed to higher dosing. The company is reviewing cash resources and potential financing alternatives and states there is no assurance of obtaining financing on acceptable terms, or at all.

Positive

• None.

Negative

• Nasdaq trading suspension effective October 31, 2025, following noncompliance with the $2,500,000 stockholders’ equity requirement, increasing liquidity and pricing risk.
• Company discloses review of cash resources and financing alternatives with no assurance of obtaining financing, signaling funding uncertainty.

Insights

Equity markets specialist

Nasdaq suspension is a material trading and liquidity setback.

The panel’s denial and suspension on October 31, 2025 move CERO off Nasdaq after failing the $2,500,000 stockholders’ equity requirement under Rule 5550(b). Delisting typically reduces visibility and may widen bid-ask spreads versus a national exchange listing.

The company will seek review by the Council and is pursuing OTC Markets while evaluating other exchanges. Actual trading venue and liquidity will depend on acceptance outcomes; the filing notes the OTC Markets are less liquid, which can affect trading price and volume.

CERO highlights ongoing clinical trials and early observations for CER-1236 at low dose. However, the company is assessing cash resources and financing alternatives with no assurance of success, so capital availability remains a key dependency for trial progression.

false 0001870404 0001870404 2025-10-29 2025-10-29 0001870404 CERO:CommonStockParValue0.0001PerShareMember 2025-10-29 2025-10-29 0001870404 CERO:WarrantsEachWholeWarrantExercisableForOneTwothousandthsOfShareOfCommonStockMember 2025-10-29 2025-10-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

CERO THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40877		87-1088814
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification Number)

201 Haskins Way, Suite 230, South San Francisco, CA		94080
(Address of principal executive offices)		(Zip Code)

(650) 407-2376

Registrant’s telephone number, including area code

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		CERO		NASDAQ Capital Market
Warrants, each whole warrant exercisable for one two-thousandths of a share of common stock		CEROW		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. 

As previously disclosed, on August 28, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), received a letter from the staff at the Nasdaq Listing Qualifications department notifying the Company that such staff had determined that the Company does not comply with the minimum stockholders’ equity requirement of $2,500,000 (the “Stockholders’ Equity Requirement”) for continued listing on the Nasdaq Capital Market (“Nasdaq”) set forth in Nasdaq Rule 5550(b).

As also previously disclosed, on September 3, 2025, the Company requested a hearing to appeal such determination before a panel (the “Hearings Panel”). On October 29, 2025, the Company received the determination of the Hearings Panel to deny the Company’s request for the continued listing of its common stock. As a result, the common stock will be suspended from trading on Nasdaq at open of trading on October 31, 2025.

The Company has submitted a request for review of the Hearings Panel’s decision by the Nasdaq Listing and Hearing Review Council (the “Council”). The Company has also commenced the process of seeking to trade its shares of common stock on the OTC Markets. However, the Company can provide no assurance that the review by the Council will result in the continued listing of its shares of common stock or that the shares of common stock will be admitted for trading on the OTC Markets. The OTC Markets also are a less liquid market than Nasdaq, which may have a material adverse effect on the trading price and volume for the common stock. The Company is also considering listing alternatives, including applying to list its shares of common stock on another securities exchange.

The Company currently plans to continue its clinical trials, including the dosing of patients in such trials. As described previously by CERO, evidence gathered for CER-1236 in the first three AML cancer patients dosed at the initial low dose showed rapid cell expansion of CER-1236 in these patients, along with observation of no toxicity.  Moreover the second patient, infused with three of the low doses in succession, continues on trial.  The company believes these early stage observations support continued clinical development of CER-1236 at the planned higher dose, and is progressing on this plan. The Company is currently reviewing its cash resources and potential financing alternatives to fund its continued operations. The Company can provide no assurance that it will be able to obtain such financing on acceptable terms, or at all.

Item 8.01. Other Events. 

On October 29, 2025, the Company issued a press release announcing the Hearings Panel’s determination. Such press release is filed as Exhibit 99.1 hereto and is hereby incorporated by reference herein. 

Item 9.01 Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release dated October 29, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CERO THERAPEUTICS HOLDINGS, INC.
	By:	/s/ Chris Ehrlich
	Name:	Chris Ehrlich
	Title:	Chief Executive Officer

Dated: October 29, 2025

2

FAQ

What did CERO (CERO) announce regarding its Nasdaq listing?

A Hearings Panel denied continued listing; CERO’s common stock will be suspended from trading on October 31, 2025.

Why is CERO out of compliance with Nasdaq rules?

It did not meet the Nasdaq Capital Market minimum stockholders’ equity requirement of $2,500,000 under Rule 5550(b).

Is CERO appealing the delisting decision?

Yes. The company requested review by the Nasdaq Listing and Hearing Review Council.

Where might CERO’s shares trade after suspension?

CERO has begun the process to trade on the OTC Markets and is considering other exchanges.

What does CERO say about liquidity on OTC Markets?

It notes OTC Markets are less liquid than Nasdaq, which may adversely affect the trading price and volume.

What operational updates did CERO share?

It plans to continue clinical trials of CER-1236, citing early low-dose observations with rapid cell expansion and no observed toxicity in initial AML patients.

How is CERO addressing funding needs?

The company is reviewing cash resources and financing alternatives and states there is no assurance of obtaining financing on acceptable terms, or at all.